Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2017 | Promising results from the CLINVO study for Non-Small Cell Lung Cancer patients

Nicolas Girard, MD, from the Claude Bernard University, Lyon, France, discusses results from the CLINVO study, a retrospective study of patients treated with Nivolumab, part of the French expanded access program. This follow up study set out to understand the further efficacy in the real-life setting of nivolumab in the advanced line treatment of non-small cell lung cancer (NSCLC), but also to understand the subsequent treatments of the failure of nivolumab. Results showed promising response rates and a good overall survival of nivolumab in the setting of patients with the failure of multiple lines of chemotherapy. The second finding of CLINIVO, showed the efficacy of subsequent treatment given just after the failure of nivolumab. The majority of patients who received single agent chemotherapy, taxane, had a good response rate and a high PFS. Dr Girard explains that overall, this study has shown some very interesting data. The next steps are to understand what is behind these findings which will be the topics of the future studies conducted with the French inter group and this cohort of patients.
Recorded at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.